Defined Bioscience Licenses FGF2-STAB (G3) for Use in Stem Cell Media

Defined recently concluded a licensing agreement with Czech Republic-based Enantis for global use of Enantis’ patented FGF2-STAB® technology both alone and in stem cell media formulations. FGF2-STAB®, originally coined FGF2-G3, was developed by Enantis and Masaryk University, using... - August 30, 2021

Defined Bioscience Launches with $1.5M SBIR from the NIH to Advance Stem Cell Media

Defined recently received a $1.5M in Phase II SBIR award from the National Institutes of Health to develop defined media over the next two years. - July 03, 2021

Press Releases 1 - 2 of 2